Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T cell response to dust mite allergens is a critical component of allergic diseases like asthma and rhinitis. It involves the activation of CD4+ T cells, particularly Th2 cells, upon recognition of dust mite-derived peptides presented by antigen-presenting cells. This leads to the production of cytokines that promote IgE production, eosinophil recruitment, and airway inflammation. Understanding the specific allergens and T cell epitopes involved is crucial for developing targeted immunotherapies.
Modulation of T cell activation, cytokine production, and effector cell recruitment in response to dust mite allergens. Immunotherapy aims to induce T cell tolerance or shift the T cell response away from Th2 dominance.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T Cell Response to Dust Mite Allergens (HDM T Cell Response).